Stammdaten
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
Unternehmen & Branche
| Name | Longeveron Inc. |
|---|---|
| Ticker | LGVN |
| CIK | 0001721484 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 20,6 Mio. USD |
| Beta | -0,19 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 1,199,000 | -22,704,000 | -1.29 | 10,261,000 | 5,675,000 |
| 2025-09-30 | 10-Q | 137,000 | -7,221,000 | -0.39 | 15,557,000 | 9,966,000 |
| 2025-06-30 | 10-Q | 316,000 | -5,028,000 | -0.33 | 16,749,000 | 12,656,000 |
| 2025-03-31 | 10-Q | 381,000 | -5,011,000 | -0.34 | 20,848,000 | 17,158,000 |
| 2024-12-31 | 10-K | 2,392,000 | -15,973,000 | -2.62 | 25,558,000 | 21,887,000 |
| 2024-09-30 | 10-Q | 773,000 | -4,419,000 | -0.34 | 29,909,000 | 25,627,000 |
| 2024-06-30 | 10-Q | 468,000 | -3,413,000 | -1.83 | 19,393,000 | 14,909,000 |
| 2024-03-31 | 10-Q | 548,000 | -4,058,000 | -1.61 | 9,697,000 | 3,041,000 |
| 2023-12-31 | 10-K | 709,000 | -21,413,000 | -10.22 | 12,078,000 | 6,741,000 |
| 2023-09-30 | 10-Q | 150,000 | -5,106,000 | -2.79 | 11,625,000 | 6,632,000 |
| 2023-06-30 | 10-Q | 217,000 | -5,632,000 | -2.67 | 17,093,000 | 11,263,000 |
| 2023-03-31 | 10-Q | 279,000 | -4,647,000 | -2.21 | 21,808,000 | 16,318,000 |
| 2022-12-31 | 10-K | 1,222,000 | -18,835,000 | -0.90 | 27,413,000 | 20,503,000 |
| 2022-09-30 | 10-Q | 265,000 | -5,244,000 | -0.25 | 30,515,000 | 24,615,000 |
| 2022-06-30 | 10-Q | 466,000 | -5,624,000 | -0.27 | 35,325,000 | 29,381,000 |
| 2022-03-31 | 10-Q | 370,000 | -3,510,000 | -0.17 | 39,173,000 | 34,306,000 |
| 2021-12-31 | 10-K | 1,306,000 | -17,045,000 | -0.90 | 42,766,000 | 37,453,000 |
| 2021-09-30 | 10-Q | 232,000 | -4,855,000 | -0.25 | 27,150,000 | 22,333,000 |
| 2021-06-30 | 10-Q | 489,000 | -5,010,000 | -0.26 | 29,857,000 | 24,650,000 |
| 2021-03-31 | 10-Q | 376,000 | -3,111,000 | 32,432,000 | 26,495,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-08-11 | Locklear Lisa | Officer, Chief Financial Officer | Open Market Purchase | 11,766 | 0.00 | 0.00 | 0,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.